- Home
- SLG vs LEGN Comparison
SLG vs LEGN Comparison
Compare SLG & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLG | LEGN |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.6B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SLG | LEGN |
|---|---|---|
| Price | $51.08 | $19.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 12 |
| Target Price | $50.63 | ★ $61.33 |
| AVG Volume (30 Days) | 719.9K | ★ 1.7M |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | ★ 7.29% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,003,046,000.00 | N/A |
| Revenue This Year | N/A | $42.68 |
| Revenue Next Year | N/A | $30.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.18 | N/A |
| 52 Week Low | $34.77 | $16.24 |
| 52 Week High | $60.93 | $37.50 |
Technical Indicators
Market Signals| Indicator | SLG | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 47.36 |
| Support Level | $48.65 | $16.98 |
| Resistance Level | $53.00 | $19.36 |
| Average True Range (ATR) | 1.64 | 0.88 |
| MACD | -0.25 | 0.13 |
| Stochastic Oscillator | 24.39 | 46.48 |
Price Performance
Historical ComparisonAbout SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 31.4 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.